Ototoxicity in Pediatric Hematopoietic Stem Cell Transplantation With High‐Dose Carboplatin: Identifying Modifiable Risk Factors Through the Inclusion of Younger Patients
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31926 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Anne Spence und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Hematology Oncology, Washington University in St. Louis, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Carboplatin, Hematopoietic Stem Cell Transplantation, Ototoxicity, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
Carboplatin ototoxicity is observed when used in high doses. We investigated risk factors associated with ototoxicity in high‐dose carboplatin hematopoietic stem cell transplantation (cHSCT) in a pediatric population.
Methods
We completed a retrospective analysis of medical and audiologic records for patients who underwent autologous cHSCT from January 1, 2008 to June 30, 2022. We accepted audiograms with a minimum requirement of threshold data at 4 kHz in at least one ear, allowing us to assess younger, more difficult to test patients and focus on hearing losses at important speech frequencies. Three audiologic outcome measures were evaluated—worsening in SIOP grade, significant change in hearing, and ototoxicity for audiograms with data up to 4 kHz and data up 8 kHz.
Results
Forty‐three cHSCTs from 29 patients had sufficient audiologic data. Ototoxicity was observed in 49% of the data up to 4 kHz and in 78% of the data up to 8 kHz. Cumulative dose of prior cisplatin (OR = 1.01, 95% CI = 1.002–1.014, p = 0.011) and cumulative dose of carboplatin in the preparative regimen (OR = 1.003, 95% CI = 1.001–1.004, p = 0.001), were associated with ototoxicity. Concurrent furosemide with carboplatin administration resulted in 100% ototoxicity, with patients demonstrating a mean change in SIOP grades by 2.0 SE ± 0.038.
Conclusion
Using criterion that allowed for the evaluation of very young children, this report demonstrates that cumulative dose of prior cisplatin, cumulative dose of carboplatin in the preparative regimen, and concomitant furosemide administration with carboplatin is associated with ototoxicity in cHSCT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Pediatric Hematology Oncology, Washington University in St. Louis, St. Louis, Missouri, USA.
- Biostatistics Shared Resource, Division of Public Health Sciences, Department of Surgery, The Alvin J. Siteman Comprehensive Cancer Center, School of Medicine, Washington University, St. Louis, Missouri, USA.
ORCID-Profile: Anne Spence, Miranda Camet, Mary Claire McGlynn, Robert J Hayashi
Förderung
- NCI NIH HHS
Zitieren
APA
Spence, A., Camet, M., Hayashi, S. S., McGlynn, M. C., Wu, N., & Hayashi, R. J. (2025). Ototoxicity in Pediatric Hematopoietic Stem Cell Transplantation With High‐Dose Carboplatin: Identifying Modifiable Risk Factors Through the Inclusion of Younger Patients. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31926
Vancouver
Spence A, Camet M, Hayashi SS, McGlynn MC, Wu N, Hayashi RJ. Ototoxicity in Pediatric Hematopoietic Stem Cell Transplantation With High‐Dose Carboplatin: Identifying Modifiable Risk Factors Through the Inclusion of Younger Patients. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31926
BibTeX
@article{Spence2025,
author = {Spence, Anne and Camet, Miranda and Hayashi, Susan S and McGlynn, Mary Claire and Wu, Ningying and Hayashi, Robert J},
title = {Ototoxicity in Pediatric Hematopoietic Stem Cell Transplantation With High‐Dose Carboplatin: Identifying Modifiable Risk Factors Through the Inclusion of Younger Patients},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31926}
}
EUVIMED